Physician profile
Robert Alfred Schnapper
NPI 1871539809
$1,388.77
in general payments reported to CMS, 2019-2025
24 companies · $21.78 in 2025
The $21.78 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $610 · 2020: $411 · 2021: $254 · 2022: $65.33 · 2024: $26.77 · 2025: $21.78.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $48.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $48.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $213.46 | 2019-2020 | |
| Ucb, INC. | $196.23 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $167.28 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $126.90 | 2019-2020 | |
| Amgen INC. | $119.77 | 2019-2021 | |
| Abbvie INC. | $67.17 | 2021-2022 | |
| Harmony Biosciences LLC | $48.55 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $44.75 | 2020-2021 | |
| Genzyme Corporation | $41.00 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $39.08 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $34.66 | 2021 | |
| Adamas Pharmaceuticals, INC. | $33.51 | 2020-2021 | |
| Allergan, INC. | $32.66 | 2020 | |
| Biogen, INC. | $30.05 | 2022 | |
| Sunovion Pharmaceuticals INC. | $29.44 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aprecia Pharmaceuticals, LLC | $23.35 | 2020 | |
| Horizon Therapeutics Plc | $22.77 | 2021 | |
| Mdd US Operations, LLC | $21.12 | 2020 | |
| Emd Serono, INC. | $18.89 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $18.40 | 2022 | |
| Neurelis, INC. | $16.75 | 2021 | |
| Acadia Pharmaceuticals INC | $16.65 | 2019 | |
| Upsher-Smith Laboratories LLC | $13.29 | 2020 | |
| Sk Life Science, INC. | $13.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Schnapper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.